Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages 3709-3716

  Jones, Helen ^a   Sprung, Victoria S ^a   Pugh, Christopher J A ^a   Daousi, Christina ^b   Irwin, Andrew ^b   Aziz, Nabil ^c   Adams, Valerie L ^d   Thomas, E Louise ^e   Bell, Jimmy D ^e   Kemp, Graham J ^d   Cuthbertson, Daniel J ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; HOMEOSTASIS; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER FAT; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SKELETAL MUSCLE FAT; WHOLE BODY MRI;

ADIPOSE TISSUE; ADULT; BODY COMPOSITION; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; LIVER; MUSCLE, SKELETAL; OBESITY; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS;

EID: 84867238072     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1382     Document Type: Article

References (33)

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF 2009 The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456-488
2. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-47
3. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T 1992 Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41:1257-1266
4. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G, Rini G 2007 Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92:2500-2505 (Pubitemid 47037349)
5. Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ, Teede HJ 2011 Effects of exercise on insulin resistance and body composition in overweight and obesewomenwith and without polycystic ovary syndrome. J Clin Endocrinol Metab 96:E48-E56
6. Lord J, Thomas R, Fox B, Acharya U, Wilkin T 2006 The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 113:1203-1209 (Pubitemid 44401216)
7. Sung KC, Kim SH 2011 Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 96:1093-1097
8. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H 2002 Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028 (Pubitemid 34816338)
9. Cohen JC, Horton JD, Hobbs HH 2011 Human fatty liver disease: old questions and new insights. Science 332:1519-1523
10. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M 2007 Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47:412-417 (Pubitemid 47176161)
11. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ 2006 Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 91:1741-1747
12. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W 2007 Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 5:496-501 (Pubitemid 46575354)
13. Baranova A, Tran TP, Birerdinc A, Younossi ZM 2011 Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33:801-814
14. Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A 2010 Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 95:343-348
15. Carmina E 2007 Need for liver evaluation in polycystic ovary syndrome. J Hepatol 47:313-315 (Pubitemid 47176169)
16. Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G, Kaltsas G 2010 Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 93:1220-1226
17. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL 2005 Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:E462-E468 (Pubitemid 40110657)
18. Mathur RS, Moody LO, Landgrebe S, Williamson HO 1981 Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. Fertil Steril 35:29-35 (Pubitemid 11168911)
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
20. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH 2004 Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395 (Pubitemid 39657013)
21. Vanhamme L, van den Boogaart A, Van Huffel S 1997 Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129:35-43 (Pubitemid 127454051)
22. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Doré CJ, Goldin RD, Bell JD, Taylor-Robinson SD 2005 Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54:122-127 (Pubitemid 40007230)
23. Rico-Sanz J, Thomas EL, Jenkinson G, Mierisová S, Iles R, Bell JD 1999 Diversity in levels of intracellular total creatine and triglycerides in human skeletal muscles observed by (1) H-MRS. J Appl Physiol 87:2068-2072
24. Perneger TV 1998 What's wrong with Bonferroni adjustments. BMJ 316:1236-1238 (Pubitemid 28171344)
25. Cussons AJ, Watts GF, Mori TA, Stuckey BGA 2009 Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 94:3842-3848
26. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I 2010 Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25:212-220
27. Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN 2010 Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 95:3332-3341
28. Chazenbalk G, Chen YH, Heneidi S, Lee JM, Pall M, Chen YD, Azziz R 2012 Abnormal expression of genes involved in inflammation, lipid metabolism, and Wnt signaling in the adipose tissue of polycystic ovary syndrome. J Clin Endocrinol Metab 97:E765-E770
29. Barber TM, Wass JA, McCarthy MI, Franks S 2007 Metabolic characteristics ofwomenwith polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 66:513-517 (Pubitemid 46434931)
30. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA 2007 Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 30:89-94 (Pubitemid 46052504)
31. Shojaee-Moradie F, Baynes KC, Pentecost C, Bell JD, Thomas EL, Jackson NC, Stolinski M, Whyte M, Lovell D, Bowes SB, Gibney J, Jones RH, Umpleby AM 2007 Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia 50:404-413
32. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP 2007 The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846-854 (Pubitemid 46631552)
33. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, and NASH Clinical Research Network 2009 Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7:1104-1112